1. Home
  2. LCTX vs PAYS Comparison

LCTX vs PAYS Comparison

Compare LCTX & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • PAYS
  • Stock Information
  • Founded
  • LCTX 1990
  • PAYS 1995
  • Country
  • LCTX United States
  • PAYS United States
  • Employees
  • LCTX N/A
  • PAYS N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • PAYS Business Services
  • Sector
  • LCTX Health Care
  • PAYS Consumer Discretionary
  • Exchange
  • LCTX Nasdaq
  • PAYS Nasdaq
  • Market Cap
  • LCTX 118.8M
  • PAYS 141.9M
  • IPO Year
  • LCTX N/A
  • PAYS 1998
  • Fundamental
  • Price
  • LCTX $0.41
  • PAYS $2.12
  • Analyst Decision
  • LCTX Strong Buy
  • PAYS Strong Buy
  • Analyst Count
  • LCTX 5
  • PAYS 3
  • Target Price
  • LCTX $4.20
  • PAYS $5.67
  • AVG Volume (30 Days)
  • LCTX 1.8M
  • PAYS 249.8K
  • Earning Date
  • LCTX 03-10-2025
  • PAYS 03-25-2025
  • Dividend Yield
  • LCTX N/A
  • PAYS N/A
  • EPS Growth
  • LCTX N/A
  • PAYS N/A
  • EPS
  • LCTX N/A
  • PAYS 0.07
  • Revenue
  • LCTX $9,499,000.00
  • PAYS $58,384,552.00
  • Revenue This Year
  • LCTX $25.10
  • PAYS $15.03
  • Revenue Next Year
  • LCTX $35.67
  • PAYS $10.61
  • P/E Ratio
  • LCTX N/A
  • PAYS $30.36
  • Revenue Growth
  • LCTX 6.19
  • PAYS 23.50
  • 52 Week Low
  • LCTX $0.40
  • PAYS $2.03
  • 52 Week High
  • LCTX $1.56
  • PAYS $5.59
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 26.71
  • PAYS 32.90
  • Support Level
  • LCTX $0.47
  • PAYS $2.03
  • Resistance Level
  • LCTX $0.55
  • PAYS $2.64
  • Average True Range (ATR)
  • LCTX 0.04
  • PAYS 0.14
  • MACD
  • LCTX -0.00
  • PAYS -0.02
  • Stochastic Oscillator
  • LCTX 8.18
  • PAYS 14.75

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

Share on Social Networks: